Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 378

Results For "US"

8882 News Found

Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market
Healthcare | June 30, 2025

Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market

The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028


Briefs: Neuland Laboratories and Granules India
Drug Approval | June 29, 2025

Briefs: Neuland Laboratories and Granules India

Granules India receives 1 observation from USFDA for Chantilly facility


Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr
News | June 29, 2025

Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr

Acquisition to be followed by merger; strengthens Torrent’s IPM market presence


FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels
Drug Approval | June 28, 2025

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access


EMA starts review of sodium oxybate in alcohol dependence
Policy | June 28, 2025

EMA starts review of sodium oxybate in alcohol dependence

Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse


Shukra Pharmaceuticals receives LoA from RMSCL
News | June 28, 2025

Shukra Pharmaceuticals receives LoA from RMSCL

The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan


European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME
Drug Approval | June 28, 2025

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME


Biocon Biologics receives Health Canada approval for Yesafili
Drug Approval | June 27, 2025

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data


Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation
News | June 27, 2025

Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation

Star Health Insurance is modernising its claims ecosystem to be future-ready


Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Biotech | June 26, 2025

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability